The non-linear (NLS) diagnostics of Biophilia Tracker X4 MAX are based on the new physics of quantum-entropic interactions, allowing to obtain maximum information during medical examinations on the gravity, maturity and intensity of functional changes in the human organism. In most cases, the application of this technology is of principle importance for diagnosis and therefore has important implications for the selection of appropriate treatment options. Therefore, the development of this method has become a major advance in diagnostic medicine. The Institute of Practical Psychophysics (IPP) began to design an NLS diagnostic system using NLS diagnostic principles and based on the research of academician Svyatoslav Pavlovich Nesterov, who invented the underlying trigger sensor. The first batch of systematic clinical trials were conducted from 1992 to 1999. At the beginning of the new century, commercial manufacturing of systems grew rapidly, and the quality of results obtained improved significantly.

Nonlinear diagnostic methods are still under development. Diagnostic methods are advancing so rapidly that versions of the system are updated every six months. The development of NLS technology is inseparable from the main problems of medicine - the causes of disease development, early diagnosis and the targeting of treatment efficiency. Despite the decrease in mortality from cardiovascular diseases (according to World Statistics), the situation surrounding the "epidemic". 1" remains negative. Continued growth in oncological and genetic diseases is being documented. In the modern world, protective, less invasive, bloodless surgeries are combined with increasingly "aggressive" treatments. If we Considering that our civilization is technological, then humanity is likely to face new unknown diseases in the future. In this context, the development of diagnostic methods continues, and NLS research should be one of the most important.

Biophilia Tracker X4 MAX continues to advance with medical development and becomes a better health product.